Graphene AI for pharma companies resolved a rare disease paradox on what the patient wants

In the new world of ESG and social responsibility, many pharma companies must be lauded for taking on initiatives to invest in providing patients with all the support they need to deal with their diseases.

One such virtuous initiative by one of the pharma companies which had a portfolio of rare disease drugs, was to start a broad-based, 3600 support program for rare disease patients.

When they engaged with Graphene AI, they expected to find specific areas of drug availability and pricing to be the most relevant to patient needs. However, the domain experts at Graphene AI advised the pharma company to take a broader approach.

The result? The AI discovered that there were such pressing challenges with dealing with the disease from a social, economic, and Quality of life standpoint that were unaddressed, as drug availability and price were for pharma companies.